Alterations in epigenetic marks (i.e., hypermethylation events) are useful biomarkers; for example, MGMT epigenetic alterations are useful biomarkers in glioblastomas [5] and GSTP1 alterations are useful in prostate cancers [6]. The gene discussed is GSTP1; the disease is prostate cancer.